A subscription to JoVE is required to view this content. Sign in or start your free trial.
In this protocol, retinitis pigmentosa patient induced pluripotent stem cell (iPSC)-derived 3D retinal organoids were generated. Those organoids successfully recapitulated some clinical phenotypes of the retinitis pigmentosa disease.
Retinitis pigmentosa (RP) is a rare and inherited retinal degenerative disease with a prevalence of approximately 1/4,000 people worldwide. The majority of RP patients have progressive photoreceptor degeneration leading to peripheral vision loss, night blindness, and finally, total blindness. To date, thousands of mutations in more than 90 genes have been reported to be associated with RP. Currently, there are few animal models available for all the affected genes and different types of mutations, which largely hampers the deciphering of the mechanisms underlying the gene/mutation pathology and limits treatment and drug development. Patient induced pluripotent stem cell (iPSC)-derived 3D retinal organoids (ROs) have provided a better system to model the human early-onset disease than cells and animals. In order to study RP, those patient-derived 3D retinal organoids were utilized to recapitulate the clinical phenotypes of RP. In the RP patient-derived ROs, Rhodopsin mislocalization was clearly displayed. Compared with other animal models, patient iPSC-derived retinal organoid models more closely recapitulated RP features and represent an ideal approach for investigating the disease pathogenesis and for drug development.
Human retinal diseases, such as retinitis pigmentosa and age-related macular degeneration, are poorly understood due to the lack of appropriate experimental models1,2. Although the mouse retina is very similar to the human retina and is a powerful tool for studying the etiology of retinal degeneration, there are huge species differences between mice and humans3,4. For instance, the nuclear architecture of the photoreceptor cells in mice and humans is different, and the mouse retina does not possess a macula5,
The protocol follows the guidelines of Capital Medical University's human research ethics committee.
1. Cell culture and generation of iPSCs
The schematic illustration describes the differentiation procedures to generate healthy and patient iPSC-derived retinal organoids (Figure 1). From iPSC to ROs, variations can be produced owing to several factors. The status of the iPSC is the determinant step of the RO generation. In addition, it is highly recommended that researchers should record every step, catalog, and lot number of all media so that the entire experiments are trackable. In Figure 2A, the i.......
Retinal organoids are 3D, laminated structures derived from hiPSCs or embryonic stem cells (ESCs) and feature as a very promising model to mimic the spatial and temporal patterns of human retinal development31,32. The ROs consist of various types of retinal cells, including photoreceptors, bipolar cells, ganglion cells, amacrine cells, horizontal cells, and Müller glia33. 2D culture cannot precisely mimic the orientation and developme.......
We thank M.S. Yan-ping Li and Zhuo-lin Liu for their technical support and helpful comments regarding the manuscript. This work was partly supported by the National Natural Science Foundation of China (82171470, 31871497, 81970838, Z20J00122), Beijing Municipal Natural Science Foundation (Z200014, 82125007), and National Key R&D Program of China (2017YFA0105300).
....Name | Company | Catalog Number | Comments |
96 V-bottomed conical wells | Sumitomo Bakelite | MS-9096VZ | |
A-83–01 | R&D Systems | 2939/10 | |
Adhesion microscope slides | CITOtest | 188105 | |
Agarose | Gene Tech | 111760 | |
Amaxa Nucleofector 2b Device | Lonza | AAB-1001 | Transfection system |
B-27 | Thermo Fisher Scientific | 17504044 | |
bFGF | R&D Systems | 3718-FB | |
Blebbistatin | Nuwacell Biotechnologies | RP01008 | |
Blood collection tube | BD Vacutainer EDTA | 366643 | |
CHIR99021 | TOCRIS | 4423/10 | |
Cover slides | CITOGLAS | 10212440C | |
cTarget hPSC Medium | Nuwacell Biotechnologies | RP01020 | |
DAPI | Invitrogen | D-1306 | |
DMEM/Ham’s F12 | Gibco | 10565-042 | |
Donkey anti-mouse 488 | Invitrogen | A-21202 | |
Donkey anti-rabbit 594 | Invitrogen | A-21207 | |
EDTA | Nuwacell Biotechnologies | RP01007 | |
Embedding medium | FluorSaveTM Reagent | 345789 | |
EX-CYTE growth enhancement medium | Sigma | 811292 | Growth enhancement medium |
Fetal bovine serum | Gibco | 04-002-1A | |
Ficoll | Sigma-Aldrich | 26873-85-8 | Density gradient medium |
FLT3L | Peprotech | 300-19 | |
GlutaMAX | Life Technologies | 35050-061 | L-glutamine supplement |
HA-100 | STEMCELL Technologies | 72482 | |
Ham’s F12 | Gibco | 11765-054 | |
hLIF | Thermo Fisher Scientific | AF-250-NA | |
Homogenizer | EDEN lab | D-130 | |
IL-3 | Peprotech | 213-13 | |
IL-6 | Peprotech | 200-06 | |
Iscove’s Modified Dulbecco Medium | Gibco | 12440053 | |
KnockOut Serum Replacement - Multi-Species | Gibco | A3181502 | Serum replacement media |
L/M-opsin | Millipore | ab5405 | |
Monothioglycerol | Sigma | M6145 | |
N-2 supplement | Thermo Fisher Scientific | 17502048 | |
Nanodrop Spectrophotometer | Thermo Fisher Scientific | ND2000 | Spectrophotometer |
ncEpic 125x Supplement | Nuwacell Biotechnologies | RP01001-02 | 125x Supplement |
ncEpic Basal Medium | Nuwacell Biotechnologies | RP01001-01 | Basal hpsc medium |
ncLaminin511 human recombinant protein | Nuwacell Biotechnologies | RP01025 | |
PD0325901 | STEMCELL Technologies | 72182 | |
Penicillin-streptomycin | Gibco | 15140-122 | |
Recombinant human BMP4 | R&D Systems | 314-BP | |
Retinoic acid | Sigma | R2625 | |
Rhodopsin | Sigma | O4886 | |
RNeasy Mini Kit | Qiagen | 74104 | |
RNeasy Mini Kit | Qiagen | 74104 | |
sIL6-R | Thermo Fisher Scientific | RP-75602 | |
StemSpan SFEM medium | STEMCELL Technologies | 09600 | |
Taurine | Sigma | T8691 | |
Trizol reagent | Invitrogen | 15596026 | |
Vitronectin | Nuwacell Biotechnologies | RP01002 | |
V-Lance knife | Alcon Surgical | 8065912001 |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved